Abstract
Introduction: the most prevalent endocrine cancer is thyroid cancer (TC), which has a low death rate despite a rising frequency. In order to assess the clinical results of novel immunotherapeutic approaches in TC, this systematic review and meta-analysis will concentrate on treatment-related adverse events (AEs), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Methods: a thorough search was done on PubMed, Embase, and ClinicalTrials.gov, covering research published between January 2018 and December 2023. The inclusion criteria were satisfied by 14 research, including a range of TC subtypes and study methodologies.Results: the effectiveness of immunotherapy varied throughout TC subtypes. In advanced TC with PD-L1 positivity, pembrolizumab showed a 9 % ORR and a 7-month PFS. In advanced/metastatic TC, camrelizumab + famitinib demonstrated ORRs of 33,3 %-62,5 % and 8,4-month PFS. Patients who tested positive for PD-L1 had greater responses to spartalizumab (19 % ORR) in ATC. Combination treatments, such as pembrolizumab and lenvatinib, demonstrated encouraging outcomes in ATC and poorly differentiated thyroid cancer (PDTC), with 34,3 % ORRs and a significant increase in PFS. With the fixed-effects model, the pooled ORR was 40,8 % (95 % CI, 37,2 %-44,5 %), and with the random-effects model, it was 33,4 % (95 % CI, 20,8 %-48,9 %). Considerable heterogeneity (I2 = 94,4 %, p < 0,01) demonstrated varying treatment outcomes across several immunotherapy protocols. Conclusion: immunotherapy has promise in the treatment of advanced tuberculosis, especially aggressive forms such as ATC, especially when used in combination regimens. Subsequent investigations have to concentrate on refining combination tactics and finding biomarkers for patient selection
Publisher
Salud, Ciencia y Tecnologia